모세혈관확장성 운동실조증(AT) : 시장 인사이트, 역학, 시장 예측(-2034년)

Ataxia Telangiectasia (AT) - Market Insight, Epidemiology, and Market Forecast - 2034

US $ 7,950 ￦ 11,017,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 16,525,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 22,034,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 33,051,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 주요 7개국의 모세혈관확장성 운동실조증(AT) 시장을 조사했으며, 질환 배경·개요, 역학, 치료와 관리의 개요, 시장 성장 촉진요인과 장벽, 미충족 요구, 출시약 및 파이프라인약의 개요, 주요 국가의 시장 규모 추이·예측, 경쟁 구도 등을 정리하고, 최적의 기회를 발굴하고, 시장의 잠재력을 평가합니다.

대상 지역

• 미국
• 유럽 5개국(독일·프랑스·이탈리아·스페인·영국)
• 일본

조사 기간 : 2020-2034년

리포트 하이라이트

• 모세혈관확장성 운동실조증(AT) 시장은 질환에 대한 인식의 향상과 의료 지출의 세계 증가에 의해 향후 수년간 변화를 보일 것으로 생각되고 있습니다.
• 기업 및 연구기관은 모세혈관확장성 운동실조증(AT)의 연구개발에 영향을 미칠 가능성이 있는 과제를 분석하고 기회를 모색하기 위해 노력하고 있습니다. 개발중인 치료제는 병태를 치료/개선하기 위한 신규 어프로치에 초점을 맞추고 있습니다.
• 대기업은 모세혈관확장성 운동실조증(AT) 치료제의 개발에 참여하고 있습니다. 새로운 치료제의 출시는 시장에 큰 영향을 미칠 전망입니다.
• 모세혈관확장성 운동실조증(AT)용 신규 치료제의 개발에는 질환 병태의 보다 깊은 이해가 필요합니다.
• 당사의 개발 단계별(제III상 및 제II상) 파이프라인 어셋에 관한 상세한 분석, 다양한 신규 동향, 상세한 임상 개요, 주요 크로스 경쟁, 발매일, 제품 개발 활동을 포함한 파이프라인약의 비교 분석은 연구개발 활동의 전체적인 시나리오를 식별하는 것으로 치료 포트폴리오에 관한 의사결정 프로세스에서 클라이언트를 지원합니다.

목차

제1장 주요 인사이트

제2장 모세혈관확장성 운동실조증(AT) : 개요

제3장 모세혈관확장성 운동실조증(AT) : 경쟁 분석

제4장 모세혈관확장성 운동실조증(AT) : 시장 개요

• 전체 시장 점유율(%) 분포 : 2020년
• 전체 시장 점유율(%) 분포 : 2034년

제5장 모세혈관확장성 운동실조증(AT) : 질환 배경·개요

• 징후와 증상
• 병태생리
• 위험인자
• 진단

제6장 환자 여정

제7장 모세혈관확장성 운동실조증(AT) : 역학·환자 인구

• 역학 : 주요 조사 결과
• 전제·근거 : 주요 7개국
• 역학 시나리오 : 주요 7개국
  • 주요 7개국 모세혈관확장성 운동실조증(AT) 역학 시나리오 : 2020-2034년
• 역학 : 미국
• 역학 : 유럽 5개국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 역학 : 일본

제8장 치료 알고리즘·현재 치료제·의료 행위

• 모세혈관확장성 운동실조증(AT) 치료와 관리
• 모세혈관확장성 운동실조증(AT) 치료 알고리즘

제9장 미충족 요구

제10장 모세혈관확장성 운동실조증(AT) 치료 주요 엔드포인트

제11장 출시 제품

• 주요 7개국의 출시 제품 리스트
• 의약품명·기업명
  • 제품 설명
  • 규제 마일스톤
  • 기타 개발 활동
  • 중요 임상시험
  • 주요 임상시험의 개요

제12장 신규 치료제

• 주요 크로스 경쟁
• 의약품명·기업명
  • 제품 설명
  • 기타 개발 활동
  • 임상 개발
  • 안전성과 유효성
  • 제품 개요

제13장 모세혈관확장성 운동실조증(AT) : 주요 7개국 시장 분석

• 주요 조사 결과
• 주요 7개국 시장 규모
• 주요 7개국 시장 규모 : 치료제별

제14장 속성 분석

제15장 주요 7개국 : 시장 전망

• 미국 : 시장 규모
• 유럽 5개국 : 시장 규모·전망
• 독일
• 프랑스
• 이탈리아
• 스페인
• 영국
• 일본 시장의 전망

제16장 모세혈관확장성 운동실조증(AT) : 액세스와 상환 개요

제17장 KOL의 견해

제18장 시장 성장 촉진요인

제19장 시장의 장벽

제20장 부록

제21장 DelveInsight 능력

제22장 면책사항

제23장 DelveInsight 소개

KSA

영문 목차

영문목차

DelveInsight's "Ataxia Telangiectasia (AT) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Ataxia Telangiectasia (AT), historical and forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Ataxia Telangiectasia (AT) market report provides current treatment practices, emerging drugs, Ataxia Telangiectasia (AT) market share of the individual therapies, current and forecasted Ataxia Telangiectasia (AT) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Ataxia Telangiectasia (AT) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Ataxia Telangiectasia (AT) Disease Understanding and Treatment Algorithm

The DelveInsight Ataxia Telangiectasia (AT) market report gives a thorough understanding of the Ataxia Telangiectasia (AT) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Ataxia Telangiectasia (AT).

Treatment

It covers the details of conventional and current medical therapies available in the Ataxia Telangiectasia (AT) market for the treatment of the condition. It also provides Ataxia Telangiectasia (AT) treatment algorithms and guidelines in the United States, Europe, and Japan.

Ataxia Telangiectasia (AT) Epidemiology

The Ataxia Telangiectasia (AT) epidemiology division provide insights about historical and current Ataxia Telangiectasia (AT) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Ataxia Telangiectasia (AT) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Ataxia Telangiectasia (AT) Epidemiology

The epidemiology segment also provides the Ataxia Telangiectasia (AT) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Ataxia Telangiectasia (AT) Drug Chapters

Drug chapter segment of the Ataxia Telangiectasia (AT) report encloses the detailed analysis of Ataxia Telangiectasia (AT) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Ataxia Telangiectasia (AT) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Ataxia Telangiectasia (AT) treatment.

Ataxia Telangiectasia (AT) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Ataxia Telangiectasia (AT) treatment.

Ataxia Telangiectasia (AT) Market Outlook

The Ataxia Telangiectasia (AT) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Ataxia Telangiectasia (AT) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Ataxia Telangiectasia (AT) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Ataxia Telangiectasia (AT) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Ataxia Telangiectasia (AT) market in 7MM.

The United States Market Outlook

This section provides the total Ataxia Telangiectasia (AT) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Ataxia Telangiectasia (AT) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Ataxia Telangiectasia (AT) market size and market size by therapies in Japan is also mentioned.

Ataxia Telangiectasia (AT) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Ataxia Telangiectasia (AT) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Ataxia Telangiectasia (AT) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Ataxia Telangiectasia (AT) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Ataxia Telangiectasia (AT) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Ataxia Telangiectasia (AT) emerging therapies.

Reimbursement Scenario in Ataxia Telangiectasia (AT)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Ataxia Telangiectasia (AT) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Ataxia Telangiectasia (AT) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Ataxia Telangiectasia (AT) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Ataxia Telangiectasia (AT), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Ataxia Telangiectasia (AT) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Ataxia Telangiectasia (AT) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Ataxia Telangiectasia (AT) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Ataxia Telangiectasia (AT) market

Report Highlights:

• In the coming years, Ataxia Telangiectasia (AT) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Ataxia Telangiectasia (AT) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Ataxia Telangiectasia (AT). Launch of emerging therapies will significantly impact the Ataxia Telangiectasia (AT) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Ataxia Telangiectasia (AT)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Ataxia Telangiectasia (AT) Report Insights

• Patient Population
• Therapeutic Approaches
• Ataxia Telangiectasia (AT) Pipeline Analysis
• Ataxia Telangiectasia (AT) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Ataxia Telangiectasia (AT) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Ataxia Telangiectasia (AT) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Ataxia Telangiectasia (AT) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Ataxia Telangiectasia (AT) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Ataxia Telangiectasia (AT) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Ataxia Telangiectasia (AT) market size during the forecast period (2024-2034)?
• At what CAGR, the Ataxia Telangiectasia (AT) market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Ataxia Telangiectasia (AT) market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Ataxia Telangiectasia (AT) market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Ataxia Telangiectasia (AT)?
• What is the historical Ataxia Telangiectasia (AT) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Ataxia Telangiectasia (AT) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Ataxia Telangiectasia (AT)?
• Out of all 7MM countries, which country would have the highest prevalent population of Ataxia Telangiectasia (AT) during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Ataxia Telangiectasia (AT) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Ataxia Telangiectasia (AT) in the USA, Europe, and Japan?
• What are the Ataxia Telangiectasia (AT) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Ataxia Telangiectasia (AT)?
• How many therapies are developed by each company for Ataxia Telangiectasia (AT) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Ataxia Telangiectasia (AT) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Ataxia Telangiectasia (AT) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ataxia Telangiectasia (AT) and their status?
• What are the key designations that have been granted for the emerging therapies for Ataxia Telangiectasia (AT)?
• What are the global historical and forecasted market of Ataxia Telangiectasia (AT)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Ataxia Telangiectasia (AT) market
• To understand the future market competition in the Ataxia Telangiectasia (AT) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Ataxia Telangiectasia (AT) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Ataxia Telangiectasia (AT) market
• To understand the future market competition in the Ataxia Telangiectasia (AT) market

Table of Contents

1. Key Insights

2. Executive Summary of Ataxia Telangiectasia (AT)

3. Competitive Intelligence Analysis for Ataxia Telangiectasia (AT)

4. Ataxia Telangiectasia (AT): Market Overview at a Glance

• 4.1. Ataxia Telangiectasia (AT) Total Market Share (%) Distribution in 2020
• 4.2. Ataxia Telangiectasia (AT) Total Market Share (%) Distribution in 2034

5. Ataxia Telangiectasia (AT): Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Ataxia Telangiectasia (AT) Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Ataxia Telangiectasia (AT) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Ataxia Telangiectasia (AT) Treatment and Management
• 8.2. Ataxia Telangiectasia (AT) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Ataxia Telangiectasia (AT) Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Ataxia Telangiectasia (AT): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Ataxia Telangiectasia (AT) Market Size in 7MM
• 13.3. Ataxia Telangiectasia (AT) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Ataxia Telangiectasia (AT) Total Market Size in the United States
  • 15.1.2. Ataxia Telangiectasia (AT) Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Ataxia Telangiectasia (AT) Total Market Size in Germany
  • 15.3.2. Ataxia Telangiectasia (AT) Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Ataxia Telangiectasia (AT) Total Market Size in France
  • 15.4.2. Ataxia Telangiectasia (AT) Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Ataxia Telangiectasia (AT) Total Market Size in Italy
  • 15.5.2. Ataxia Telangiectasia (AT) Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Ataxia Telangiectasia (AT) Total Market Size in Spain
  • 15.6.2. Ataxia Telangiectasia (AT) Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Ataxia Telangiectasia (AT) Total Market Size in the United Kingdom
  • 15.7.2. Ataxia Telangiectasia (AT) Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Ataxia Telangiectasia (AT) Total Market Size in Japan
  • 15.8.3. Ataxia Telangiectasia (AT) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Ataxia Telangiectasia (AT)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

관련자료